45,256 Maze Therapeutics, Inc. $MAZE Shares Bought by Profund Advisors LLC

Key Points

• Profund Advisors increased its Maze Therapeutics position by 410.5% in the third quarter, purchasing 45,256 additional shares and ending with 56,281 shares worth approximately $1.53 million.
• Maze shares opened at $30.37, with a market capitalization of about $1.69 billion. The company reported quarterly EPS of -$0.76, matching estimates, and analysts expect a full-year EPS loss of $2.70.
• Analyst sentiment remains positive, with a consensus “Buy” rating and an average price target of $64.45, although insiders sold 192,991 shares worth roughly $5.19 million over the past three months.

Profund Advisors LLC increased its position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 410.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,281 shares of the company's stock after buying an additional 45,256 shares during the quarter. Profund Advisors LLC owned about 0.10% of Maze Therapeutics worth $1,530,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Sterling Capital Management LLC grew its holdings in Maze Therapeutics by 390.5% during the third quarter. Sterling Capital Management LLC now owns 1,089 shares of the company's stock worth $30,000 after acquiring an additional 867 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the 2nd quarter valued at about $48,000. Royal Bank of Canada lifted its holdings in Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company's stock valued at $61,000 after acquiring an additional 1,383 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Maze Therapeutics in the 2nd quarter valued at about $80,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Maze Therapeutics during the 2nd quarter valued at about $200,000.

Maze Therapeutics Price Performance

NASDAQ MAZE opened at $30.37 on Tuesday. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a fifty day simple moving average of $27.51 and a 200 day simple moving average of $31.94. The company has a market cap of $1.69 billion, a P/E ratio of -12.05 and a beta of 2.16. Maze Therapeutics, Inc. has a 1 year low of $21.95 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). On average, sell-side analysts predict that Maze Therapeutics, Inc. will post -2.70 EPS for the current year.

Wall Street Analysts Forecast Growth

MAZE has been the topic of several recent research reports. BTIG Research reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Wedbush reiterated an "outperform" rating and issued a $48.00 target price on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. Citigroup started coverage on Maze Therapeutics in a research note on Wednesday, September 23rd. They set a "buy" rating and a $50.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $110.00 price target on shares of Maze Therapeutics in a research note on Thursday, September 24th. Finally, TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $64.45.

Insider Activity

In related news, insider Atul Dandekar sold 7,500 shares of the business's stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $32.07, for a total transaction of $240,525.00. Following the completion of the transaction, the insider owned 32,316 shares of the company's stock, valued at approximately $1,036,374.12. The trade was a 18.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the business's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $27.02, for a total value of $932,217.02. Following the transaction, the chief executive officer directly owned 15,558 shares of the company's stock, valued at $420,377.16. This represents a 68.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 192,991 shares of company stock valued at $5,187,559 over the last three months. 5.30% of the stock is currently owned by insiders.

Maze Therapeutics Profile

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze's pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.

Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.